AptarGroup earnings beat by $0.05, revenue topped estimates
AptarGroup (NYSE: ATR) reported Q3 EPS of $1.52, beating estimates by $0.05, with revenue at $1.02B, above consensus. Q4 2026 EPS guidance is $1.39-$1.47. Stock is down 2.48% in 3 months but up 5.05% in 12 months. InvestingPro rates its financial health as good.
How this was made
The 30-second read
Why it matters
EPS and revenue both beat consensus, and Q4 guidance ($1.39-$1.47) sits slightly above the $1.41 consensus, which can drive a positive re-rating if investors focus on earnings trajectory.
Market read
Traders can update expectations for AptarGroup’s near-term earnings trajectory based on the beat and the Q4 guidance range.
What to watch
The article does not discuss margins, cash flow, or segment performance, which can dominate post-earnings moves even when EPS and revenue beat.
Background
This is AptarGroup’s Q3 earnings report with a stated Q4 2026 EPS outlook.
Ticker impact
AptarGroup reported Q3 EPS of $1.52, beating the $1.47 estimate, and revenue of $1.02B versus $981.45M consensus.
Likely upward bias as traders price in stronger-than-expected earnings power and modestly constructive Q4 guidance.
The article provides the company’s own quarterly results and explicit Q4 EPS guidance range versus consensus, which are direct drivers of earnings re-rating.
Market effects
Supports sentiment for packaging and drug-delivery supply-chain names by signaling demand resilience and execution.
Primarily US-listed single-name impact; limited spillover beyond industrial/healthcare supply chains.
Modest, as the disclosure is company-specific rather than a global macro or regulatory shift.
Counterpoint
The guidance range is only modestly above consensus, so the stock reaction could be muted if investors were already positioned for a beat.
Key entities
- companyAptarGroup
NYSE-listed drug-delivery and packaging supplier reporting Q3 results and issuing Q4 EPS guidance.
